Quote Request
Adenosquamous Carcinoma
Alfa Cytology provides specialized services tailored to the intricate demands of adenosquamous carcinoma research, a distinct and aggressive variant of pancreatic cancer. Leveraging cutting-edge technology and deep expertise, we aim to advance the understanding of adenosquamous carcinoma pathogenesis, identify novel therapeutic targets, and support the preclinical development of innovative treatments.
Introduction to Adenosquamous Carcinoma
Adenosquamous carcinoma is a rare and aggressive subtype of pancreatic cancer characterized by the presence of both glandular (adenocarcinoma) and squamous cell carcinoma components. It primarily affects organs such as the lungs, pancreas, cervix, and esophagus. Adenosquamous carcinoma constitutes approximately 1-4% of all pancreatic cancer cases and is associated with a poorer prognosis compared to pancreatic adenocarcinoma. This carcinoma exhibits unique histopathological features, including the coexistence of two distinct cell types, which complicates its diagnosis and treatment.
Fig. 1 Squamous cell carcinoma and adenosquamous cell carcinoma formation. (Zhang, W.; et al., 2023)
Therapeutics for Adenosquamous Carcinoma
The development of targeted therapies for adenosquamous carcinoma is a promising and rapidly evolving area of research. Several drugs are currently in various stages of the developmental pipeline, and here are some key examples.
| Therapeutics | Molecular Type | Target | Phase |
|---|---|---|---|
| AMG 510 | Small Molecule Inhibitor | KRAS G12C | Phase II |
| Pembrolizumab | Monoclonal Antibody | PD-1 | Phase III |
| Olaparib | Small Molecule Inhibitor | PARP | Phase III |
| Durvalumab | Monoclonal Antibody | PD-L1 | Phase III |
| Ipilimumab | Monoclonal Antibody | CTLA-4 | Phase II |
| Tislelizumab | Monoclonal Antibody | PD-1 | Phase III |
| Lenvatinib | Multi-kinase Inhibitor | VEGFR, FGFR, PDGFR, RET, KIT | Phase III |
| Bempegaldesleukin | Pathway Agonist | IL-2 receptor | Phase III |
| Evorpacept | Small Molecule Inhibitor | CD47 | Phase II |
Our Services
Alfa Cytology offers a comprehensive suite of research services, including basic research, in vitro and in vivo modeling, molecular characterization, drug screening, and therapeutic efficacy testing, etc. Our main goal is to promote groundbreaking research for new therapeutic approaches, contributing to the broader effort of combating pancreatic cancer.
Basic Research Services for Adenosquamous Carcinoma
Alfa Cytology provides robust therapeutic development services aimed at advancing treatments for adenosquamous carcinoma. These services encompass the entire drug development pipeline from initial screening to preclinical testing.
Adenosquamous Carcinoma Biology Research Services
- Cancer Cell-based Assay
- Cell Signaling Pathway Analysis
- Single Cell ICP-MS
Molecular Biology Services
- Analysis of Gene Mutations in Tumors
- Molecular Characterization of Tumor Metastasis
- Analysis of Epigenetic Regulation in Tumors
- Identification of Molecular Subtypes in Tumors
- Analysis of Non-coding RNA-mediated Regulation in Tumors
Progression and Metabolic Analysis
- Tumorigenesis and Metastasis Analysis
- Cancer Metabolism Analysis
Therapeutic Development Services
Alfa Cytology provides robust therapeutic development services aimed at advancing treatments for adenosquamous carcinoma. These services encompass the entire drug development pipeline from initial screening to preclinical testing.
Small Molecule Drug Development
Identification and optimization of small molecules targeting key pathways and genetic mutations involved in adenosquamous carcinoma.
Immunotherapy
Design and testing of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies to enhance the immune response against adenosquamous carcinoma.
Exploration of gene-editing technologies, such as CRISPR/Cas9, to correct genetic defects and inhibit tumor growth.
Biologic Therapeutics
Development of monoclonal antibodies, vaccines, and other biologics targeting specific antigens and signaling pathways.
Preclinical Research Services
By employing different study models and techniques, Alfa Cytology can comprehensively evaluate the safety, efficacy and pharmacokinetic properties of anti-adenosquamous carcinoma drugs, laying a solid foundation for subsequent trials.
- In Vitro Efficacy Evaluation
- In Vivo Efficacy Evaluation
DMPK/ADME for Drugs
- Toxicology Evaluation
- Immunogenicity and Immunotoxicity Evaluation
Case Study - Pancreatic Ductal Adenocarcinoma (PDAC) PDX Model
- Model Introduction
The pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (PDX) model established with primary human pancreatic cancer cells provides a highly translational preclinical platform for evaluating novel immunotherapeutic strategies targeting the cancer stem cell (CSC) population. This model recapitulates key molecular features of human PDAC, including high expression of CD47 on cancer stem cells, enabling the study of macrophage-mediated phagocytosis and its role in overcoming chemoresistance.
- Model Information
- Model: Pancreatic Ductal Adenocarcinoma (PDAC) PDX Model
- Animal: NU-Foxn1nu Nude Mice
- Weight: 18-22 g
- Cancer Type: Pancreatic Ductal Adenocarcinoma (PDAC)
- Age: 6-8 Weeks
- Molecular Profile: High CD47 expression on cancer stem cells (CD133+/CD47+), heterogeneous CD47 expression across tumor samples.
- Model Construction
Primary PDAC tissue fragments (approximately 2 mm3) derived from patient samples were subcutaneously implanted into the flanks of immunodeficient NU-Foxn1nu nude mice. Tumor growth was monitored until reaching approximately 100 mm3, after which mice were randomized into treatment groups for therapeutic evaluation.
Fig. 2 Workflow of pancreatic ductal adenocarcinoma (PDAC) PDX model establishment and treatment. (Source: Alfa Cytology)
- In Vivo Efficacy Evaluation
This study employed the established PDAC PDX models to systematically evaluate the antitumor efficacy of CD47 inhibition as monotherapy and in combination with standard chemotherapies.
- Anti-CD47 Treatment: Anti-CD47 monotherapy showed limited efficacy in the PDX model, resulting in only a marginal reduction in tumor growth compared to control groups.
- Chemotherapy Monotherapy: Drug A demonstrated moderate antitumor activity but did not prevent tumor relapse after treatment discontinuation. Similarly, drug B (50 mg/kg every 4 days) showed an initial tumor response but eventually led to disease relapse.
- CD47 and Chemotherapy Combination Therapy: The combination of anti-CD47 with chemotherapy demonstrated significantly enhanced efficacy. In the PDX model, the combination of drug A/B plus anti-CD47 resulted in sustained tumor regression without relapse, whereas drug A/B alone led to tumor regrowth after treatment cessation.
Fig. 3 In vivo treatment effect. (Left) Tumour volume. *p < 0.01 vs. Single treatment, **p < 0.01 vs. Control (n = 6). (Right) CD133 expression on the surface of cells isolated from tumors in treated mice. *p < 0.01 vs. Single treatment, **p < 0.01 vs. Control (n = 6). Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology is dedicated to advancing the field of pancreatic cancer research through our specialized preclinical services. Our comprehensive offerings, including therapeutic development, cancer modeling, and analytical services, are tailored to meet the unique challenges of adenosquamous carcinoma. The types of molecules we can develop involve small-molecule drugs, therapeutic antibodies, peptide drugs, gene therapies, cellular therapies, and more. For more information on our services and how we can support your research endeavors, please contact us.
Reference
- Zhang W, et al. Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. Cell Oncol (Dordr). 2023, 46(1):1-15.
